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INTRODUCTION
Nitric Oxide (NO) is a signaling molecule responsible for several 
physiological and pathophysiological actions throughout the human 
body, including blood flow control and modulation of immune 
res ponse(1,2). In mammals, NO is considered to circulate as S-nitro-
sothiols, mainly S-nitrosoglutathione (GSNO), S-nitrosoalbumin and 
pos sibly S-nitrosohemoglobin(3,4). Synthetic GSNO and S-nitroso-N-
ace tylcysteine (SNAC) were already used as exogenous NO donors in 
different experimental settings(5,6). 
In the eye, NO has been shown to be a key regulator of vascular 
tone in ophthalmic arteries(7,8) and animal and human studies have 
demonstrated reduction in the choroidal blood flow with systemic 
infusion of NO inhibitors(9-11). NO donors were also shown to increa-
se blood flow in the retina, choroid and the optic nerve head(12,13). 
Additionally, some studies have addressed the beneficial effect of 
S-nitrosothiols on the reduction of intraocular pressure(14-17), and sug-
gest that S-nitrosothiols are potential new drugs for the treatment of 
glaucoma and other ocular ischemic diseases(13). 
Nitric oxide-mediated antimicrobial activity has also been the fo cus 
of recent research(18,19). GSNO and SNAC displayed bactericidal and 
bac teriostatic activities against several Gram-positive and Gram-ne -
gative clinical isolates from patients with bacterial infectious kerati-
tis(20). In addition, GSNO and SNAC were also shown to exert potent 
antimicrobial actions against trophozoites of Acanthamoe ba castellanii, 
the etiological agent responsible for a devastating si ght-threatening 
keratitis(21). These data suggest that NO donors are important candi-
dates for treating infectious eye diseases. Other possible therapeutic 
applications of S-nitrosothiols in ophthalmology include corneal 
wound healing(22), antifibrotic effect in glaucoma filtering surgery(23) 
and anti-inflammatory action in autoimmune uveitis(24). 
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ABSTRACT
Purpose: To evaluate the ocular surface toxicity of two nitric oxide donors in ex 
vivo and in vivo animal models: S-nitrosoglutathione (GSNO) and S-nitroso-N-
ace tylcysteine (SNAC) in a hydroxypropyl methylcellulose (HPMC) matrix at final 
concentrations 1.0 and 10.0 mM. 
Methods: Ex vivo GSNO and SNAC toxicities were clinically and histologically 
ana lyzed using freshly excised pig eyeballs. In vivo experiments were performed 
with 20 albino rabbits which were randomized into 4 groups (5 animals each): 
Groups 1 and 2 received instillations of 150 µL of aqueous HPMC solution con-
taining GSNO 1.0 and 10.0 mM, respectively, in one of the eyes; Groups 3 and 4 
received instillations of 150 µL of aqueous HPMC solution-containing SNAC 1.0 and 
10.0 mM, respectively, in one of the eyes. The contralateral eyes in each group 
received aqueous HPMC as a control. All animals underwent clinical evaluation 
on a slit lamp and the eyes were scored according to a modified Draize eye test 
and were histologically analyzed. 
Results: Pig eyeballs showed no signs of perforation, erosion, corneal opacity or 
other gross damage. These findings were confirmed by histological analysis. The re 
was no difference between control and treated rabbit eyes according to the Draize 
eye test score in all groups (p>0.05). All formulations showed a mean score under 
1 and were classified as “non-irritating”. There was no evidence of tissue toxicity 
in the histological analysis in all animals. 
Conclusion: Aqueous HPMC solutions containing GSNO and SNAC at concentra-
tions up to 10.0 mM do not induce ocular irritation. 
Keywords: Drug toxicity; S-nitrosothiols; S-nitrosoglutathione; Methylcellulose; 
Ni tric oxide donors
RESUMO
Objetivo: Avaliar a toxidade na superfície ocular de dois compostos doadores de 
óxido nítrico em modelos ex vivo e in vivo: S-nitrosoglutationa (GSNO) e S-nitroso- 
N-acetilcisteína (SNAC), em uma matriz de hidroxipropil metilcelulose (HPMC) nas 
concentrações finais de 1,0 and 10,0 mM. 
Métodos: As toxicidades de GSNO e SNAC foram avaliadas clinicamente e histolo-
gicamente em modelo ex vivo usando globos oculares porcinos recém excisados. 
Experimentos in vivo foram realizados com 20 coelhos albinos que foram randomiza -
dos em 4 grupos (5 animais em cada): Os grupos 1 e 2 receberam instilações de 150 µL 
de solução aquosa de HPMC contendo GSNO 1,0 e 10,0 mM, respectivamente, em 
um dos olhos; Os grupos 3 e 4 receberam instilações de 150 µL de solução aquosa de 
HPMC contendo SNAC 1,0 and 10,0 mM, respectivamente, em um dos olhos. Os olhos 
contralaterias em cada grupo receberam solução aquosa de HPMC como controle. 
Todos os animais foram clinicamente avaliados em lâmpada de fenda e os olhos foram 
pontuados de acordo com o teste de Draize modificado e analisados histologicamente. 
Resultados: Os globos oculares porcinos não apresentaram sinais de perfuração, 
erosão, opacidade da córnea ou outros danos graves. Esses resultados foram con-
firmados pela análise histológica. Não houve diferença entre os olhos dos coelhos 
tratados e controles de acordo com a pontuação do teste de Draize em todos os 
grupos (p>0,05). Todas as formulações apresentaram um escore médio menor do 
que 1 e foram classificadas como “não-irritantes”. Não houve evidência de toxicidade 
tecidual nas análises histológicas em todos os animais. 
Conclusão: Soluções aquosas de HPMC contendo GSNO e SNAC em concentrações 
até 10,0 mM não induzem irritação ocular. 
Descritores: Toxicidade de drogas; S-nitrosotióis; S-nitrosoglutationa, Metilcelulose; 
Doadores de óxido nítrico
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Despite these potential clinical applications of S-nitrosothiols in 
ophthalmology, the ocular toxicity of these compounds is not yet 
known. The purpose of the present study was to evaluate the ocular 
surface toxicity of GSNO and SNAC after topical installations in ex vivo 
and in vivo animal models. 
METHODS
Materials 
Glutathione (g-Glu-Cys-Glu, GSH), N-acetyl-cysteine (NAC), sodium 
nitrite (NaNO2), hydrochloric acid (HCl), phosphate buffer saline so -
lution, pH 7.4 (PBS) and acetone were purchased from Sigma (St. 
Louis, MO, USA) and used as received. Ketamine and xylazine hydro-
chlorides were purchased from Phoenix Scientific Inc. (St. Joseph, MO, 
USA). Hydroxypropyl methylcellulose (HPMC) was manufactured by 
Dow Chemical Company (Midland, MI, USA).
synthesis of Gsno and snaC
GSNO and SNAC were synthesized as previously described(25). 
SNAC solutions were prepared from a freshly made stock solution 
40.0 mM and further diluted in PBS to 2.0 and 20.0 mM with a final 
pH 7.0. GSNO solutions 2.0 and 20.0 mM, pH 7.0, were prepared im-
mediately before use from solid GSNO.
PreParation of s-nitrosothiols-ContaininG hPMC forMulations
SNAC and GSNO concentrations 1.0 and 10.0 mM in HPMC solu-
tion 2% (w/v) were prepared by mixing equal volumes of aqueous 
HPMC solution 4% (w/v) and SNAC or GSNO solutions 2.0 or 20.0 mM, 
prepared as above, under stirring. These formulations were designa-
ted as SNAC 1, SNAC 10, GSNO 1 and GSNO 10, respectively.
stability of the hPMC-ContaininG s-nitrosothiols forMulations
The concentrations of SNAC and GSNO in the HPMC formulations 
were spectrophotometrically monitored during their storage in the 
dark at 37ºC for 1 h, based on their characteristic optical absorption 
bands at 336 nm, assigned to the -SNO moiety. A Diode-array spec-
trophotometer (HP-8453, Hewlett-Packard, Palo Alto, CA, USA) was 
used for this purpose. GSNO and SNAC solutions 10 mmol L-1 were 
monitored over 1 h in a 1 cm optical path quartz cuvette. Concentra-
tion changes in the solutions were calculated based on the molar ab-
sorption coefficient of GSNO and SNAC (900.0 mol-1L cm-1 at 336 nm). 
aniMals
Male New Zealand healthy albino rabbits (1.8 to 2.2 kg) were pur -
chased from the Center of Development of Experimental Models for 
Medicine and Biology (CEDEME, São Paulo, Brazil). All animals were 
handled in accordance with the NIH Principles of laboratory animal 
care and the ARVO statement for the use of animals in ophthalmic 
and vision research. The experimental protocol was previously appro-
ved by the Research Ethics Committee from Federal University of São 
Paulo. All animals were acclimated and housed in individual cages 
(designed to avoid accidental injury) and kept in a room with 12-h 
light-dark diurnal cycle, adequate air turnover and constant tempera-
ture (22°C), receiving standard rabbit chow (Purina, São Paulo, Brazil) 
and water ad libitum. All procedures were performed under systemic 
anesthesia with intramuscular injection of 30 mg/kg of ketamine hy -
drochloride and 5 mg/kg of xylazine hydrochloride.
Ex vivo evaluation 
For ethical reasons, the toxicities of the S-nitrosothiols formula-
tions were previously evaluated in an ex vivo model to lessen the 
likelihood of any non-selective effects in rabbit eyes during the in 
vivo tests. Twenty-five freshly excised pig eyeballs were obtained 
from a local slaughterhouse immediately after slaughter, washed 
thoroughly with PBS and divided into five groups. The eyeballs of 
each of four experimental groups were instilled with 500 μL of SNAC 
1, SNAC 10, GSNO 1 or GSNO 10 formulations onto the cornea and 
conjunctiva.
The fifth group received the same volume of pure HPMC solution 
2% (w/v) and served as a control. The eyeballs were clinically analyzed 
under a surgical microscope before instillation and 30 min and 1 h 
after instillation. The eyeballs were fixed in 10% formalin solution for 
48 h, stained with hematoxylin-eosin and subjected to histological 
analysis.
oCular tolerability
Twenty rabbits were randomized into 4 groups with 5 animals 
each: groups 1 and 2 received instillations of 150 mL of GSNO 1 and 
GSNO 10, respectively, in one eye (randomly chosen by coin toss bet -
ween right or left side); groups 3 and 4 received 150 mL of SNAC 1 and 
SNAC 10, respectively, in one eye (randomly chosen as above). The 
contralateral eye of each animal received aqueous HPMC as a con-
trol. A sentinel study with a single animal per group was performed 
before the entire experiment and showed no clinical and histological 
damage up to 72 h. Based on this result, the evaluation of toxicity 
was limited to 24 h.
A modified Draize test was used to access potential ocular irri-
tancy(26). Slit lamp examination was performed before drug exposure 
to ensure normal ocular surface integrity and repeated 1 and 24 h 
after drug instillation. The score system evaluated the corneal opacity 
(scored from 0 to 4), iritis (from 0 to 2) and conjunctival redness (from 
0 to 3)(26). The final score was calculated by summing the cornea, iris 
and conjunctiva scores, which ranged from 0 to 9. The score criteria 
were defined according to the following cutoffs: under 1: non-ir ri -
tating; 1 to 4: mildly irritating; 5 to 7: moderately irritating; over 7: 
severely irritating. 
After 24 h all animals were sacrificed with intravenous pentobar -
bital sodium injection under anesthesia, the eyes were enucleated, 
fixed in 10% formalin solution for 48 h and then histologically ana -
lyzed (hematoxylin-eosin stain). All the slit lamp evaluations were 
performed under double blind conditions (i.e. both the investigator 
who performed the instillations and the investigator who performed 
the histological analysis did not know the formulation identity).
statistiCal analyses 
Data were expressed as mean ± standard deviation. The compa-
risons between Draize score of control and treated eyes were done 
using the non-parametric Mann-Whitney U test. P values <0.05 indi-
cated statistical significance.
RESULTS
In the ex vivo experiment, all pig eyes showed no signs of per-
foration, tissue erosion, corneal opacity or other gross damage. The 
conjunctival and corneal epithelium were preserved and there was 
no significant difference between treated and control groups. His-
tological evaluation confirmed the absence of damage in the pig 
conjunctival and corneal epithelium and the preservation of external 
and intraocular tissue structures in the treated groups. 
In the in vivo experiments, all formulations showed a mean score 
under 1 and were classified as “non-irritating” compounds. None of 
the animals developed corneal opacity or iritis. There was no signifi-
cant difference in the mean score between control and the treated 
groups 1 and 24 h after drug instillation (p>0.05) (Table 1). The animal 
blink rate or eye wiping 5 min into the recovery period after anesthe-
sia were unaffected by drug treatment. 
The palpebral, cul-de-sac and bulbar conjunctival histologies 
of all control and treated animals were unchanged. No vessel pro-
liferation or immune cell infiltration was detected. The Goblet-cells 
were present throughout the entire conjunctival surface with no 
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cytoarchitectural modifications. The limbus was preserved and no 
inflammatory cell infiltration was noted. The cornea also had an un-
changed appearance in all its layers with no angiogenesis or inflam-
matory signs (Figure 1). No histological modifications were noted in 
the sclera, iris, lens, choroid and retina. 
Evaluation of the stability of the SNAC 10 and GSNO 10 formula-
tions at 37ºC showed that less than 2% of the SNAC or GSNO decom-
pose under this condition after 1 h.
DISCUSSION
In spite of their potential therapeutic applications, the ocular to -
xicity of GSNO and SNAC had not been characterized yet. Previous 
studies performed to evaluate the ocular hypotensive effect of other 
topical NO donors, like sodium nitroprusside and S-nitroso-N-acetyl- 
DL-penicillamine reported no adverse effects in the concentration 
range 1-2 mM(14,15). Equimolar concentrations of different NO donors 
lead to variable levels of detectable NO metabolites in vitro and in vivo 
and differences in pharmacological and pharmacokinetic properties 
of these compounds can lead to different clinical effects in ocular 
tissues(15). Thus, results obtained with a specific nitric oxide donor 
cannot always be extended to S-nitrosothiols such as GSNO and 
SNAC. This was the first standardized study to evaluate the potential 
toxic effects of topical instillation of aqueous HPMC formulations 
containing GSNO and SNAC on the surface of the eye. We chose the 
concentration 1 mM, which was previously shown to have in vitro mi-
crobicidal effects against trophozoites of Acanthamoeba castellanii(21) 
and a concentration ten times higher than this in order to explore the 
toxicity level of these RSNOs.
The Draize rabbit eye test used in the present study has been 
globally accepted since 1944 as the standard regulatory method for 
determining the ocular irritation potential of chemical products(27-30). 
However, its use has been criticized on the bases of ethical consi-
derations since it is employed on live animals. Alternative methods 
have been discussed for ocular toxicity assessment(30). Many tests 
have been published using ex vivo tissue and cell culture of animal 
and human tissue(27,30,31). Despite good reproducibility and sensitivity 
of several in vitro alternative model assays for ocular irritation, their 
predictive power was not as reliable as the rabbit Draize eye test(30). 
Moreover, the majority of these tests do not address the issue of ocu-
lar irritation reversibility(32). Ex vivo assays are accepted by regulatory 
authorities for specific and limited purposes(30). As recommended 
by regulatory agencies(27,30), in the present study a tiered testing 
stra tegy was performed to minimize consequential animal distress. 
It included concerns about the use of neutral formulations and the 
use of similar NO donors in animal eyes and ocular tissue described 
in the literature(14,15).
Considering that the cornea is an avascular tissue, topical admi-
nistration is a first choice approach for treating diseases of the ante-
rior segment of the eye such as glaucoma and keratitis(33). In addition, 
topical application may allow the use of locally high concentrations 
of active principles, with minor or non-significant side effects(33). The 
HPMC used for the topical instillations of aqueous SNAC and GSNO 
solutions in this work is a non-toxic hydrophilic mucoadhesive po -
lymer with film forming properties, commonly used in intraocular 
sur gery, topical administrations, artificial tears and drug vehicle(34,35). 
It is known that tear drainage and blinking action may result in low 
Table 1. Draize eye test score
Compounds
Interval of 
exposure
Treatment
mean ± SD
Control
mean ± SD p value*
SNAC 1 After 1 hour 0.2 ± 0.45 0.2 ± 0.45 1.00
After 24 hour 0 0 -
SNAC10 After 1 hour 0.4 ± 0.55 0.2 ± 0.45 0.69
After 24 hour 0.2 ± 0.45 0.2 ± 0.45 1.00
GSNO1 After 1 hour 0 0 -
After 24 hour 0 0 -
GSNO10 After 1 hour 0.4 ± 0.55 0.2 ± 0.45 0.69
After 24 hour 0.2 ± 0.45 0.2 ± 0.45 1.00
SNAC= S-nitroso-N-acetylcysteine; GSNO= S-nitrosoglutathione; SD= standard deviation. 
*= Mann-Whitney U test.
A
B
C
Figure 1. Representative histological images of rabbit eyes after instillation of HPMC for-
mulations containing 10.0 mM S-nitrosogluthatione (GSNO) or S-nitroso-N-acetilcysteine 
(SNAC). (A) Conjunctival cul-de-sac (arrow) (100x). (B) Conjunctival bulbar epithelium 
(arrow shows a globetcell) (200x). (C) Cornea with normal aspect of epithelium (thick 
arrow) and endothelium (thin arrow) (200x). Hematoxylin-eosin stain in all pictures.
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drug absorption following topical ocular application. This considera-
tion accounts for why HPMC solution was used as a vehicle. It acts as 
a viscosity enhancer and is expected to increase both the residence 
time of the S-nitrosothiols in the cul-de-sac and their bioavailability 
on the pre corneal tear film(36-38). Moreover, the low amount of S-ni -
trosothiols decomposition in the HPMC matrix indicates that this 
vehicle is appropriate for ocular drug delivery. 
Generally, topical drug instillation does not result in the diffusion 
of the drugs into the vitreous chamber and their pharmacological 
actions are limited to the anterior ocular surfaces not affecting the 
retina and the choroid. In fact, Behar-Cohen et al.(14) showed that 
nitrite levels were undetectable in the rabbit vitreous humor after an 
NO donor injection into the anterior chamber. The absence of histo-
logical alterations and of inflammatory infiltrates observed in our in 
vivo results is, therefore, consistent with the ex vivo results.
CONCLUSIONS
Aqueous HPMC formulations containing SNAC or GSNO up to 
10 mM display low ocular surface toxicity in topical applications 
and might be a promising option for treating ocular diseases where 
nitric oxide may have microbicidal or other beneficial pharmaceutical 
actions.
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